The study is evaluating the dose of sofosbuvir plus ribavirin in adolescent patients—aged 12 to 17 yo—infected with HCV genotype 2 and 3. Once the dose is determined the same adolescent patients will be treated with the combination of sofosbuvir plus ribavirin.
Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
To view the entire clinical trial description, click here
Share This Page